NCT06887933View on ClinicalTrials.gov

A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer

PHASE4Not yet recruitingINTERVENTIONAL

Enrollment

67

Participants

Timeline

Start Date

April 22, 2025

Primary Completion Date

March 20, 2026

Study Completion Date

July 8, 2026

Conditions

Ovarian Neoplasms

Interventions

DRUG

Niraparib

Niraparib will be administered.

Sponsors

Lead Sponsor

GlaxoSmithKline

All Listed Sponsors

lead

GlaxoSmithKline

INDUSTRY

NCT06887933 - A Trial to Evaluate the Safety of Niraparib Tablets in Adult Female Participants With Advanced or Relapsed Epithelial Ovarian Cancer | Biotech Hunter | Biotech Hunter